Literature DB >> 15781741

Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.

Andrew D Michaels1, Barry McKeown, Michael Kostal, Kalpesh T Vakharia, Mark V Jordan, Ivor L Gerber, Elyse Foster, Kanu Chatterjee.   

Abstract

BACKGROUND: Levosimendan is a calcium-sensitizing agent and an inodilator under current investigation in the treatment of decompensated heart failure. The effects of intravenous levosimendan on the human coronary vasculature, together with myocardial wall stress and oxygen uptake, have not been adequately studied. METHODS AND
RESULTS: Ten adult patients underwent right- and left-heart catheterization. Baseline coronary blood flow was determined with quantitative coronary angiography and an intracoronary Doppler-tipped guidewire. Myocardial oxygen uptake was measured with a coronary sinus catheter. Echocardiography was performed before and 30 minutes after an intravenous infusion of levosimendan (24-microg/kg bolus over 10 minutes) was begun. Pulmonary capillary wedge decreased 37% (P=0.009), cardiac output increased 9% (P=0.04), and systemic vascular resistance decreased 18% (P<0.001). Left ventricular ejection fraction increased 20% (P=0.009), and meridional systolic wall stress decreased 48% (P=0.009). Coronary artery diameter increased 10% at 15 minutes (P=0.001) and 11% at 30 minutes (P=0.01). Coronary artery velocity increased 10% over baseline (P=0.04). Coronary blood flow increased 45% (P=0.02), whereas coronary resistance decreased 36% at 30 minutes (P=0.03). Myocardial oxygen extraction decreased 9% at 30 minutes (P=0.04).
CONCLUSIONS: Levosimendan given intravenously exerts vasodilator effects on human coronary conductance and resistance arteries. Despite a decrease in coronary perfusion pressure, coronary blood flow is increased. A reduction in coronary vascular resistance and a decrease in coronary venous oxygen content indicate primary coronary vasodilation by levosimendan. Improved left ventricular systolic function and decreased myocardial oxygen extraction suggest improved myocardial efficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781741     DOI: 10.1161/01.CIR.0000159252.82444.22

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Altered coronary vascular control during cold stress in healthy older adults.

Authors:  Zhaohui Gao; Thad E Wilson; Rachel C Drew; Joshua Ettinger; Kevin D Monahan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-14       Impact factor: 4.733

2.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

3.  A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart.

Authors:  E F du Toit; A Genis; L H Opie; P Pollesello; A Lochner
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

4.  Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Authors:  Ildikó Gödény; Piero Pollesello; István Edes; Zoltán Papp; Zsolt Bagi
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

Review 5.  Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.

Authors:  Alexandre Mebazaa; Antonis A Pitsis; Alain Rudiger; Wolfgang Toller; Dan Longrois; Sven-Erik Ricksten; Ilona Bobek; Stefan De Hert; Georg Wieselthaler; Uwe Schirmer; Ludwig K von Segesser; Michael Sander; Don Poldermans; Marco Ranucci; Peter C J Karpati; Patrick Wouters; Manfred Seeberger; Edith R Schmid; Walter Weder; Ferenc Follath
Journal:  Crit Care       Date:  2010-04-28       Impact factor: 9.097

6.  Effect of levosimendan in experimental verapamil-induced myocardial depression.

Authors:  Jouni Kurola; Heli Leppikangas; Jarkko Magga; Leena Lindgren; Vesa Kiviniemi; Juha Rutanen; Esko Ruokonen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-03-11       Impact factor: 2.953

Review 7.  Structures reveal details of small molecule binding to cardiac troponin.

Authors:  Fangze Cai; Monica X Li; Sandra E Pineda-Sanabria; Shorena Gelozia; Steffen Lindert; Frederick West; Brian D Sykes; Peter M Hwang
Journal:  J Mol Cell Cardiol       Date:  2016-11-05       Impact factor: 5.000

Review 8.  Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.

Authors:  Ibrahim Halil Kurt
Journal:  Surg Today       Date:  2009-04-30       Impact factor: 2.549

Review 9.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Levosimendan: from basic science to clinical practice.

Authors:  John T Parissis; Pinelopi Rafouli-Stergiou; Ioannis Paraskevaidis; Alexandre Mebazaa
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.